ALPHA EMITTER MARKET ANALYSIS

Regional Analysis

Global Alpha Emitter Market - Regional Analysis

Among all regions, North America region is expected to dominate the market over the forecast period. This is attributed due to the increasing adoption of inorganic growth strategies such as collaborations between the key market players In order to develop and produce novel radiopharmaceuticals for the treatment of cancer is expected to drive the market growth in the region over the forecast period. For instance, in January 1, 2023, NorthStar Medical Radioisotopes (NMR), a global company specialized in the development, production, and commercialization of radiopharmaceuticals that are used for therapeutic applications and medical imaging, and Inhibrx, Inc., a clinical-stage biotechnology company, announced their collaboration to develop and produce novel radiopharmaceuticals for the treatment of cancer.

The European region is expected to second largest region over the forecast period. Europe Alpha emitter market is expected to witness significant growth over the forecast period, owing to increasing adoption of inorganic growth strategies such as supply agreements between the key market players in the region. For instance, in July 2022, Eckert & Ziegler, a provider of isotope technology for medical, scientific, and industrial use, signed a supply agreement with Precirix, a clinical-stage biotechnology company, which is dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals, for the supply of the therapeutic radioisotope named Actinium-225. This agreement will provide Precirix the access to Eckert & Ziegler's high-purity, non-carrier-added Actinium225 that is used for the labeling of trial drugs in radionuclide therapy.